The Stafford Fox Drug Discovery Facility (SF-DDF) at Murdoch Children's Research Institute offers an automated platform for high throughput/high content drug screening of patient’s induced Pluripotent Stem Cell (iPSC) derived tissues.


The objective of the Drug Discovery Facility is to enable researchers to progress in vitro disease models towards high throughput screening models for the identification of novel drug-like compounds. We contribute with drug screening campaign design, assay development and validation and drug screening for the identification of new drug candidates for the treatment of inherited diseases using human cells and tissues.

Screening Platform

The facility hasworld-first platform that aims to accelerate drug discovery. Our platform is fully integrated consisting of an automated liquid handling system (Fluent1080, TECAN), an automated rotary incubator (Cytomat5, ThermoFisher) and a high-speed confocal-based imaging system (CV8000, Yokogawa). This integrated platform istailored to enable live high throughput screening of large human organoids.


The Drug Discovery Facility was established through a generous Stafford Fox Medical Research Foundation donation. It is an NCRIS Therapeutics Innovation Australia (TIA) consortium facility. Find out more about TIA Access Vouchers.

The Facility is also supported by the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW (NNF21CC0073729).

Collaborators: Compounds Australia

Scientist in the laboratory

Discover our world-class Stem Cell Medicine research group

More about Stem Cell Medicine